Patients accrued to date

1139

Number of therapeutic protocols open

10
AZD2171 (phase I);
Avastin + Irinotecan (phase II);
MK-0752 (phase I);
GDC-0449 (phase I);
GDC-0449 - Adult (phase II);
SAHA + Isotretinoin (feasibility);
ABT-888 + Temozolomide (phase I);
AZD6244 (phase I);
Capecitabine + RT (phase II);
PTC299 (phase I)

Number of therapeutic protocols closed

20
IT mafosfamide in infants (phase I/II) ;
SU5416 (phase I);
SCH 66336 (phase I);
IT Busulfan (phase I);
O6-BG & Temodar (phase I);
STI571 (phase II);
ZD1839 + RT(phase II);
Gliadel & O6-BG (phase I);
Oxaliplatin (phase II);
Intratumoral IL-13 (phase I/II);
Celengitide (phase I);
TP-38 (phase I/II);
Zarnestra + RT (phase I);
O6-BG & Temodar (phase II);
GW572016 (phase I/II);
VNP40101M (phase I);
CC-5013 (phase I);
Intratumoral Topotecan (phase I);
Capecitabine + RT (phase I);
Enzastaurin (phase I)

Number of therapeutic protocols in development

1

Number of non-therapeutic protocols open

1

Number of non-therapeutic protocols closed

7

Number of non-therapeutic protocols in development

0

Number of concepts reviewed to date

106